blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2740793

EP2740793 - DRUG COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.10.2018
Database last updated on 01.02.2025
FormerThe patent has been granted
Status updated on  27.10.2017
FormerGrant of patent is intended
Status updated on  18.06.2017
FormerExamination is in progress
Status updated on  06.01.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Toray Industries, Inc.
1-1, Nihonbashi-Muromachi 2-chome Chuo-ku
Tokyo, 103-8666 / JP
[2014/24]
Inventor(s)01 / KOBAYASHI Shinichi
c/o Basic Research Center
Toray Industries Inc.
10-1 Tebiro 6-chome
Kamakura-shi Kanagawa 248-8555 / JP
02 / OKANO Fumiyoshi
c/o Basic Research Center
Toray Industries Inc.
10-1 Tebiro 6-chome
Kamakura-shi Kanagawa 248-8555 / JP
03 / SAITO Takanori
c/o Basic Research Center
Toray Industries Inc.
10-1 Tebiro 6-chome
Kamakura-shi Kanagawa 248-8555 / JP
 [2014/24]
Representative(s)Denison, Christopher Marcus, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2017/48]
Former [2014/24]Denison, Christopher Marcus, et al
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS / GB
Application number, filing date12819759.703.08.2012
[2017/48]
WO2012JP69857
Priority number, dateJP2011017133204.08.2011         Original published format: JP 2011171332
[2014/24]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013018892
Date:07.02.2013
Language:JA
[2013/06]
Type: A1 Application with search report 
No.:EP2740793
Date:11.06.2014
Language:EN
[2014/24]
Type: B1 Patent specification 
No.:EP2740793
Date:29.11.2017
Language:EN
[2017/48]
Search report(s)International search report - published on:JP07.02.2013
(Supplementary) European search report - dispatched on:EP02.03.2015
ClassificationIPC:C12N15/09, A61K39/395, A61K48/00, A61P35/00, A61P35/02, C07K16/30, C07K16/28, C07K16/18, A61K39/00
[2015/14]
CPC:
C07K16/30 (EP,RU,US); C07K16/18 (US); A61K39/39558 (EP,RU,US);
A61P35/00 (EP); A61P35/02 (EP); C07K16/28 (EP,US);
A61K2039/505 (EP,US); C07K2317/24 (EP,US); C07K2317/732 (EP,US) (-)
Former IPC [2014/24]C12N15/09, A61K39/395, A61K48/00, A61P35/00, A61P35/02, C07K16/30
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/24]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ARZNEIMITTELZUSAMMENSETZUNG ZUR KREBSBEHANDLUNG UND/ODER VORBEUGUNG[2014/24]
English:DRUG COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION[2014/24]
French:COMPOSITION DE MÉDICAMENT POUR TRAITEMENT ET/OU PRÉVENTION DU CANCER[2014/24]
Entry into regional phase20.02.2014Translation filed 
21.02.2014National basic fee paid 
21.02.2014Search fee paid 
21.02.2014Designation fee(s) paid 
21.02.2014Examination fee paid 
Examination procedure21.02.2014Examination requested  [2014/24]
29.09.2015Amendment by applicant (claims and/or description)
29.08.2016Despatch of a communication from the examining division (Time limit: M04)
20.12.2016Reply to a communication from the examining division
19.06.2017Communication of intention to grant the patent
21.10.2017Fee for grant paid
21.10.2017Fee for publishing/printing paid
21.10.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.08.2016
Opposition(s)30.08.2018No opposition filed within time limit [2018/45]
Fees paidRenewal fee
03.06.2014Renewal fee patent year 03
24.08.2015Renewal fee patent year 04
24.08.2016Renewal fee patent year 05
25.07.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL29.11.2017
CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MK29.11.2017
RO29.11.2017
RS29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
IS29.03.2018
LU03.08.2018
MT03.08.2018
[2020/33]
Former [2020/31]CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MK29.11.2017
RO29.11.2017
RS29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
LU03.08.2018
MT03.08.2018
Former [2020/08]CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
RO29.11.2017
RS29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
LU03.08.2018
MT03.08.2018
Former [2019/21]CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
RO29.11.2017
RS29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
LU03.08.2018
Former [2019/15]CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
RO29.11.2017
RS29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
Former [2018/52]CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
RO29.11.2017
RS29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
Former [2018/40]CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
RO29.11.2017
RS29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
Former [2018/37]CY29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
RS29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
Former [2018/25]FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
RS29.11.2017
BG28.02.2018
NO28.02.2018
Former [2018/22]FI29.11.2017
LT29.11.2017
NO28.02.2018
Documents cited:Search[Y]WO2005116076  (DEBIOVISION INC [CA], et al) [Y] 1-8 * See page 10, line 1 - page 11, line 10; claim 4 *;
 [Y]EP2322221  (TORAY INDUSTRIES [JP]) [Y] 1-8 * See § 157, 173-175; claims 1/21 *;
 [Y]EP2325648  (TORAY INDUSTRIES [JP]) [Y] 1-8* See § 99-102; 111 *
International search[A]WO2010016525  (TORAY INDUSTRIES [JP], et al);
 [A]WO2010016526  (TORAY INDUSTRIES [JP], et al);
 [A]WO2010016527  (TORAY INDUSTRIES [JP], et al);
 [A]  - GRILL B. ET AL., "Activation/Division of Lymphocytes Results in Increased Levels of Cytoplasmic Activation/Proliferation-Associated Protein-1: Prototype of a New Family of Proteins.", J.IMMUNOL., (2004), vol. 172, pages 2389 - 2400, XP002690350

DOI:   http://dx.doi.org/10.4049/jimmunol.172.4.2389
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.